Related Experiment Videos
Aortic valve replacement with cryopreserved allografts: mid-term results
1Department of Cardiothoracic Surgery, Boston University Medical Center, University Hospital, Massachusetts 02118.
Journal of Cardiac Surgery
|May 1, 1994
Summary
Cryopreserved allografts offer safe aortic valve replacement (AVR) with excellent mid-term results and durability. This method is particularly beneficial for patients with active endocarditis or prior prosthetic valve failure.
Area of Science:
- Cardiovascular Surgery
- Thoracic Surgery
- Cardiac Valve Surgery
Background:
- Aortic valve replacement (AVR) is a critical procedure for severe aortic valve disease.
- Cryopreserved allografts are an option for AVR, but their long-term efficacy requires evaluation.
- Understanding outcomes is crucial for selecting appropriate prosthetic materials.
Purpose of the Study:
- To analyze the clinical and echocardiographic mid-term outcomes of AVR using cryopreserved allografts.
- To assess the safety, efficacy, and durability of allograft AVR in a diverse patient cohort.
Main Methods:
- A cohort study was conducted at a tertiary care center.
- Fifty patients underwent allograft AVR between 1987 and 1992.
- Outcomes assessed included early mortality/morbidity, mid-term survival, functional class, valve complications, and echocardiographic function.
Main Results:
- Early mortality was 4%, with no late mortality or significant valve-related complications during a median follow-up of 34 months.
- Most patients improved to New York Heart Association (NYHA) Class I or II.
- Echocardiography revealed minimal or no aortic regurgitation in 98% of patients, indicating good valve function.
Conclusions:
- Aortic valve replacement with cryopreserved allografts is a safe procedure.
- Allograft AVR is particularly advantageous for patients with active endocarditis or malfunctioning prosthetic valves.
- Excellent mid-term clinical results and valve durability at 5 years support the use of cryopreserved allografts.